Clinical Trials Logo

MRD-positive clinical trials

View clinical trials related to MRD-positive.

Filter by:
  • None
  • Page 1

NCT ID: NCT05940961 Recruiting - Clinical trials for Hematopoietic Stem Cell Transplantation

Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

As part of postremission consolidative therapy, the decision to proceed with hematopoietic stem cell transplantation is a recommendable regimen in ALL therapy. However, The recurrence rate is high after transplantation. Minimal Residual Disease (MRD) is an important factor affecting the effect of HSCT. The hematologic recurrence rate of MRD-positive patients with adult ALL is high. MRD- is associated with better prognosis. Therefore, maintaining MRD- after transplantation is necessary for long-term survival. The purpose of this study is to explore the efficacy and safety of Inotuzumab Ozogamicin in the treatment of minimal residual disease recurrence after HSCT of ALL patients.

NCT ID: NCT03919526 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor(CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL

Start date: August 11, 2019
Phase: Phase 1
Study type: Interventional

To evaluate the safety and efficacy of CD19/CD22 Bispecific chimeric antigen receptor (CAR)-T for the treatment of measurable residual disaese (MRD)-positive B cell acute lymphoblastic leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells.